Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes

Completed · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Diabetes Mellitus, Type 2

In brief

This is a 2-3 period parallel group study with an adaptive element in Type 2 diabetes patients receiving vildagliptin as monotherapy.

Key facts

Study ID
NCT00821977
Run by
Novartis
People needed
338
Starts
2008-11-01
Expected to finish
2010-10-01
Last updated by the study team
2020-12-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.